- Information Center
- Investment News
Korean biopharmaceutical producer Samsung BioLogics Co. has completed the construction of its third plant, the world`s single largest biopharmaceutical product manufacturing facility, in Songdo, Incheon.
The four-story plant spans 118,618 square meters, twice the size of Sangam World Cup Stadium in western Seoul with an annual production capacity of 180,000 liters, according to the company on Friday.
Given the company’s current capacity of two running plants, 30,000 liters and 150,000 liters, Samsung BioLogics has a total of 360,000 liters of capacity that exceeds those of other global CMOs such as Lonza`s 260,000 liters and Boehringer-Ingelheim with 240,000 liters.
The third plant will be validated for a year and enter into pilot operations for another two years before full-scale production in the second half of 2020, the company said.
Samsung BioLogics has so far inked CMO deals with 10 global pharmaceutical brands over 15 products, which are valued at about $3.3 billion.
By Kim Hye-soon and Minu Kim
Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.
Source: Pulse by Maeil Business News Korea (Dec. 1, 2017)